Blood Transfusions Clinical Trials
A listing of Blood Transfusions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 381 clinical trials
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
- 17 views
- 19 Dec, 2022
- 20 locations
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
who are transfusion-dependent or present with symptomatic anemia.
- 1 views
- 21 Oct, 2022
- 12 locations
An observational, multi-center study to evaluate the safety of deferasirox in the treatment of pediatric patients with non-transfusion-dependent iron overload.
An observational, multi-center study to evaluate the safety of deferasirox in the treatment of pediatric patients with non-transfusion-dependent iron overload.
- 331 views
- 25 Mar, 2021
- 1 location
Eltrombopag for People With Fanconi Anemia
Fanconi anemia is a genetic disease. Some people with it have reduced blood cell counts. This means their bone marrow no longer works properly. These people may need blood transfusions for anemia
- 143 views
- 22 Dec, 2020
- 1 location
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia
) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening
- 16800 views
- 22 Aug, 2022
- 7 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US
luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The
- 54541 views
- 22 Aug, 2022
- 9 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.  
- 23120 views
- 22 Aug, 2022
- 10 locations
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease
>Eligibility: Adults ages 18-80 of African descent. They may have sickle cell disease or not. They must not have had a transfusion recently or have a known deficiency of pyruvate kinase
- 63 views
- 22 Dec, 2020
- 1 location
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
medicines, for transfusions of red blood cells and platelets, and for collecting blood samples. Preparatory chemotherapy (fludarabine, cyclophosphamide and anti-thymocyte globulin) and total body
- 54 views
- 22 Dec, 2020
- 1 location
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Donor cells infused through their central line Transfusions After about 30 days, recipients will leave the hospital. They must stay near NIH for 3 months after the
- 83 views
- 22 Dec, 2020
- 1 location